Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT plus Vibecotamab in EGFR-positive oligometastatic solid tumors
ChiCTR2600126603Phase 3Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of vibecotamab in Non-hematologic malignancy (2 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-free survival (PFS). Started Jun 2026; status: recruiting.
02
Drugs
vibecotamab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2600126603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126603.